Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

There is something deeply uncomfortable about the idea of leaving home to receive medical care when you are already unwell. Hospitals are necessary, but for many patients, they can be terribly intimidating. They want consistent, skilled support. And they want it where they are most comfortable. And home healthcare is built around. Let us understand […]

The post How Home Healthcare Services Support Patients At Home appeared first on Medical News Bulletin.

NEW ORLEANS — Results presented at the American Academy of Orthopaedic Surgeons Annual Meeting showed remote therapeutic monitoring may be safe and cost effective for patients who underwent total knee arthroplasty.
“We did not see any increase in manipulation or reoperation rates associated with using remote therapeutic monitoring, but we do see decreased costs associated with that,” Bryan T. Wall, MD, said in his presentation. “I think we have demonstrated that we can successfully deploy this technology in the geriatric patient population.”
Wall, along with Wael K. Barsoum, MD; Alison K.

Click here to read the Cover Story, “Paralympian initiates advocacy for eye care.”
Winston Churchill once said, “The price of greatness is responsibility.”
In modern eye care, that responsibility extends well beyond making the correct diagnosis or selecting the optimal surgical or medical therapy. Our obligation to patients does not end when we write the prescription or complete the procedure. It ends when the patient actually receives the care they need and benefits from it.
The pace of innovation in eye care is extraordinary. We now have advanced diagnostics, precision surgery, novel implants,

COPENHAGEN, Denmark — Neoadjuvant chemoimmunotherapy demonstrated high pathological response rates with “manageable” toxicity in patients with squamous cell lung cancer, according to data presented at European Lung Cancer Congress.
Continued monitoring of long-term immune-related adverse events is needed, according to Julio Herrero, MD, medical oncologist in lung cancer at The Christie NHS Foundation Trust.
“Squamous cell lung cancer is my main area of translational research within the Manchester Cancer Research Centre, and I wanted to evaluate the realworld safety and efficacy of this regimen

The CDC recently updated its recommendations for the prevention and treatment of tularemia for the first time in nearly 25 years based on new data from animal studies and human cases.
Tularemia, also known as rabbit fever, is caused by the bacterium Francisella tularensis, which can spread to people via the bite of infected ticks and deer flies or through contact with infected animal tissue, including when skinning rabbits or other animals that may carry it, according to the CDC. A few years ago, a biologist contracted tularemia while conducting an autopsy on a seal in Washington state.

The microbiome of the eye’s surface was not significantly different between contact lens wearers vs. non-wearers, suggesting other mechanisms may drive contact lens discomfort, according to a study in Microbiology Spectrum.
“Contact lenses are worn by millions of people, yet the scientific literature contains conflicting reports about their impact on the microbial communities that are naturally present on the eye surface,” Oriane S. Kopp, of the department of ophthalmology at Bern University Hospital, Switzerland, and colleagues wrote. “Understanding the relationship between contact lens wear,

Editor’s note: This is a developing story. Please check back soon for updates.
The FDA approved a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight with weight-related comorbidities, Eli Lilly announced.
Orforglipron (Foundayo, Eli Lilly) is an oral small molecule GLP-1 that can be taken without restrictions on food or water. The FDA’s approval of the medication was based on findings from the ATTAIN trial program.
As Healio previously reported in the ATTAIN-1 trial, adults with overweight or obesity achieved a weight loss of 7.8% with 6 mg of orforglipron, 9.3% with a

Click here to read the At Issue to this Cover Story.
As an athlete, Amy Dixon is used to overcoming adversity.
She is a member of the U.S. Paratriathlon team and has competed in eight world championships and the Tokyo 2020 Paralympic Games. When she was 22 years old, she was diagnosed with multifocal choroiditis with panuveitis. Twelve years later, she received a diagnosis of neovascular glaucoma and steroid-induced glaucoma due to the years of steroid use to treat uveitis.
“My doctors think the onset of my disease was probably when I was 10 years old,” she said. “I had rheumatic fever, a type

Adults with diabetes using an automated insulin delivery system had minimal change in time in range after switching continuous glucose monitoring sensors, according to a speaker.
As Healio previously reported in September, MiniMed received FDA clearance to allow its 780G automated insulin delivery system to be integrated with the Instinct CGM sensor (Abbott Diabetes Care). In a real-world analysis presented at the International Conference on Advanced Technologies & Treatments for Diabetes, researchers found that CGM metrics for patients who switched from the Guardian 4 sensor (MiniMed) to

DENVER — Povorcitinib, an oral JAK-1 inhibitor currently being investigated for hidradenitis suppurativa, demonstrated substantial clinical efficacy through 54 weeks, according to new data.
Patients with moderate to severe HS assigned povorcitinib (Incyte) in the STOP-HS1 and STOP-HS2 trials achieved high levels of response at week 54, and the therapy was well tolerated, Martina J. Porter, MD, FAAD, vice chair for research and academics in the department of dermatology, director of the dermatology clinical trials unit CLEARS and coleader of the Pathogens, Immunology and Inflammation